Wedbush Raises Price Target on CG Oncology to $77 From $70, Keeps Outperform Rating

Accelerated Creto Trajectory in NMIBC Drives Earlier Data, De-Risked Commercialization, and Higher $66 Target Supporting Buy Rating on CG Oncology

CG Oncology price target raised to $66 from $62 at Truist

CG Oncology price target raised to $93 from $89 at Morgan Stanley

CG Oncology Up Over 27%, on Track for Record High Close and Record Percent Increase -- Data Talk

Crude Oil Rises Sharply; US Consumer Sentiment Edges Higher In January

CG Oncology: Early PIVOT-006 Readout, Strengthened Creto Outlook, and 2026 Catalyst Wave Support Buy Rating and Higher $85 Target

CG Oncology rises 16.0%

CG Oncology Accelerates Phase 3 Bladder Cancer Trial Timeline

BRIEF-Cg Oncology Provides Updated Timeline For Pivot-006 Phase 3 Topline Data In Intermediate-Risk Nmibc

CG Oncology to Share Data for Investigational Bladder Cancer Therapy Nearly a Year Early

CG Oncology to Report PIVOT-006 Phase 3 Topline Data for Intermediate-Risk NMIBC in First Half of 2026

CG Oncology Inc - Expects Phase 3 Pivot-006 Data in 1H 2026

CG Oncology Provides Updated Timeline for Pivot-006 Phase 3 Topline Data in Intermediate-Risk Nmibc

BofA Adjusts Price Target on CG Oncology to $62 From $60, Maintains Buy Rating

SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

CG Oncology Initiated at Outperform by Wedbush